UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
Britain Courts Anthropic Amid US Defense Department Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
DUBLIN, Ireland, Jan. 27, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its fourth-quarter 2016 financial results will be released on Monday, February 27, 2017. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 57707260. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 57707260.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
